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Mediation of the effects of living in extremely
poor neighborhoods by health insurance: breast
cancer care and survival in California, 1996 to
2011
Kevin M Gorey1*, Isaac N Luginaah2, Eric J Holowaty3, Guangyong Zou4, Caroline Hamm5
and Madhan K Balagurusamy6

Abstract
Background: We examined the mediating effect of health insurance on poverty-breast cancer care and survival
relationships and the moderating effect of poverty on health insurance-breast cancer care and survival relationships
in California.
Methods: Registry data for 6,300 women with breast cancer diagnosed between 1996 and 2000 and followed until
2011 on stage at diagnosis, surgeries, adjuvant treatments and survival were analyzed. Socioeconomic data were
obtained for residences from the 2000 census to categorize neighborhoods: high poverty (30% or more poor),
middle poverty (5%-29% poor) and low poverty (less than 5% poor). Primary payers or health insurers were
Medicaid, Medicare, private or uninsured.
Results: Evidence of survival mediation was observed for women with node negative breast cancer. The apparent
effect of poverty disappeared in the presence of Medicare or private health insurance. Women who were so
insured were advantaged on 8-year survival compared to the uninsured or those insured by Medicaid (OR = 1.89).
Evidence of payer moderation by poverty was also observed for women with node negative breast cancer. The
survival advantaging effect of Medicare or private insurance was stronger in low poverty (OR = 1.81) than it was in
middle poverty (OR = 1.57) or in high poverty neighborhoods (OR = 1.16). This same pattern of mediated and
moderated effects was also observed for early stage at diagnosis, shorter waits for adjuvant radiation therapy and
for the receipt of sentinel lymph node biopsies. These findings are consistent with the theory that more facilitative
social and economic capital is available in low poverty neighborhoods, where women with breast cancer may be
better able to absorb the indirect and direct, but uncovered, costs of care. As for treatments, main protective effects
as well as moderator effects indicative of protection, particularly in high poverty neighborhoods were observed for
women with private health insurance.
Conclusions: America’s multi-tiered health insurance system mediates the quality of breast cancer care. The system
is inequitable and unjust as it advantages the well insured and the well to do. Recent health care reforms ought to
be enacted in ways that are consistent with their federal legislative intent, that high quality health care be truly
available to all.
Keywords: Health insurance, Poverty, Breast cancer care, Survival, Social capital, Health care reform, California,
United States
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Background
Studies of cancer care and survival in low-income areas
of Canada and the United States have consistently
observed Canadian advantages over the past generation
[1-5]. More inclusive health insurance in Canada has
been advanced as the most plausible explanation. These
studies were ecological with respect to the measurement
of socioeconomic status (SES). They used census tract
data to define low-income neighborhoods, however, their
lowest income areas typically only ranged from 10% to
20% poor. So they had limited power to study cancer care
among “the truly disadvantaged” that live in America’s
poorest neighborhoods where 30% to 40% or more of the
households have incomes below the poverty line [6-8].
Recent analyses have suggested several reasons for the
importance of investigating breast cancer care in such
vulnerable places [2,5]. First, breast cancer is the most
common cancer among American women and its prognosis is typically excellent with early diagnosis and
treatment [9,10]. Second, a direct association between
income and breast cancer survival has been consistently
observed [2,11]. Third, as increasingly effective screens
and treatments have proliferated evidence has mounted
that the best care is more accessible to women of higher
SES [3-5,12-17]. Fourth, being underinsured has also
been associated with less than optimum care [18-24].
These US studies have also for the most part had insufficient samples and statistical power to study the quality
of breast cancer care among those at greatest risk of not
receiving it; the very poor and the inadequately insured.
Combined effects of being underinsured and living in
extremely poor neighborhoods

International studies have allowed us to develop the theory that SES-cancer care relationships are probably
mediated by health insurance [2,25-27]. It is also probable that within the multi-payer US health care system
the effects of various health insurers interact with other
resources in ways not yet studied. However, thus far this
field has primarily focused on advancing knowledge
about main effects. More complex hypotheses about mediation and moderation effects have, for the most part,
not been formally tested [17]. A recent study of ours
may have been the first to test such effects in American
cancer care [27]. We found evidence that having health
insurance significantly mediated or buffered the povertysurvival relationship for women with colon cancer, but
not for men. We also found that poverty moderated the
health insurance-survival relationship, again only for
women. The advantaging effects of all health insurers,
public and private, were significantly larger for women
in low-poverty neighborhoods. The present study will
examine these relationships among women with breast
cancer.
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Health insurance in transaction with social capital

Our SES-health insurance-cancer care mediation theory
aims to model care gaps in America’s most vulnerable
communities. Its foundation is William Julius Wilson’s
work in 1960s Chicago’s high poverty neighborhoods
and Paul Jargowsky and Mary Jo Bane’s research in
America’s extremely poor neighborhoods in the 1970s
and 80s [6-8]. Together they described places of prevalent demographic vulnerability that were particularly distressed for their lack of social and economic capital.
Medicaid and Medicare, the government’s, respective,
mean-tested and entitlement, health insurance programs
were specifically designed to mediate the effects of such
impoverishment. But SES and public and private health
insurance probably interact in important ways across
America’s economic divide. A recent survey demonstrated how SES and health insurance can interact in the
lives of people with cancer. It surveyed mostly insured
people with colon cancer and found that more than a
third of them suffered one or more significant financial
hardships as a result of their treatment [28]. Moreover,
more than one of every ten of them reported coverage
denials by their insurers with consequent inabilities to
adhere to prescribed treatment regimes. And low-income
households were much more likely to be so impacted.
It seems that the effectiveness of various health insurance
programs may be significantly moderated by other resources.
Those most likely to be disadvantaged are the poor. It is they
who are the least likely to be able to bare the indirect (time
lost from work, child care and travel) and direct, but uncovered costs (deductibles, co-insurances and co-payments) of
contemporary cancer care in America [29].
Hypotheses

The objective of this study was to evaluate the distinct
mediating and moderating effects of SES and health
insurance on cancer care in extremely poor communities
in the US. We hypothesized that the inverse povertybreast cancer survival relationship would be significantly,
if not completely, mediated or explained by the intermediate effect of having health insurance (private, Medicare or
Medicaid). We also hypothesized a health insurance by
poverty interaction, that is, that the direct insurancebreast cancer survival relationship would be significantly
moderated by poverty (all types of health insurance would
be less effective in high poverty neighborhoods) [30,31].
We then explored similar hypotheses across breast cancer
care from diagnoses to adjuvant or palliative therapies.

Methods
The sampling frame was the California cancer registry
(CCR) which validly monitors the most populous US
state [32-34]. California seems an appropriate place
for this study as its population in high poverty
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neighborhoods nearly doubled between 1990 and 2000
while the nation’s population in high poverty neighborhoods decreased significantly [35,36]. Registry data was
obtained for 6,300 women with invasive breast cancer
diagnosed between 1996 and 2000 [37] and followed until
2011. Cases were randomly selected from three geographic place strata (2,100 cases each): megalopolises
(greater San Diego, the San Francisco Bay area and greater
Los Angeles), smaller metropolitan areas (Salinas, Modesto, Stockton, Bakersfield and Fresno) and rural places
with population densities less than 400 per km2 [38-40].
This study was powered to detect rate differences of 5%
between 3 geographic place and 3 socioeconomic strata
with 80% power at a 2-tailed significance level of 5%
[41,42].
Variables
Poverty and payers

We first linked breast cancer patients to the US (2000)
census by their residential census tracts [38]. Next, to
model our poverty measure after those that have been
the most validated, we defined the following neighborhoods: high poverty (30% or more of households poor),
middle poverty (5%-29% poor) and low poverty (less
than 5% poor) [2,5-8,43-45]. Socioeconomic distributions of our sample’s poverty tertiles are displayed in
Table 1. The prevalence of poverty in the typical high
poverty neighborhood was 37%, just about mid-point
between Wilson’s (30%) and Jargowsky and Bane’s (40%)
criterion definitions of high poverty. The typical annual
household income of $23,275 in such high poverty
neighborhoods in 2000 seems a face valid definition of
an extremely poor household. Most of this field’s heretofore low-income or “poor” samples would have fell into
this study’s middle poverty group.
Health insurance status, defined as the primary source
of payment to the hospital or primary payer, was determined from medical records during the initial course of
treatment. It was categorized as uninsured, Medicaid,
Medicare (with or without any supplementation or any
other non-means-tested governmental payer) or private
insurer (any commercial managed care corporation or
fee-for-service provider). The two key study variables of
Table 1 Prevalence of poor households in breast cancer
patients’ neighborhoods: California, 2000

Low

Range

Median
3.36

Table 2 Primary payers among women with breast cancer
in low, middle and high poverty neighborhoods:
age-adjusted prevalence estimates and standardized
prevalence ratios
Neighborhood poverty
By primary payer

Sample

Prevalence

PR

(95% CI)

Low Poverty
Uninsured

183

.086

1.00

Medicaid

25

.012

1.00

Medicare

525

.263

1.00

1,367

.638

1.00

Uninsured

226

.108

1.26

(1.04, 1.52)

Medicaid

130

.062

5.17

(3.60, 7.42)

Medicare

577

.275

1.05

(0.94, 1.17)

1,167

.555

0.87

(0.83, 0.91)

Private
Middle Poverty

Private

276

.133

1.55

(1.30, 1.85)

Medicaid

310

.151

12.58

(9.28, 17.05)

74,000

Medicare

672

.307

1.17

(1.06, 1.29)

Private

842

.408

0.64

(0.60, 0.68)

a

Income, $

Middle

5.00–29.76

11.40

44,200

High

30.09–100.00

36.84

23,275

Note. Neighborhood income derived from US Census data [38].
a
Census tract median annual household income.

Variables from hospital and physicians’ office charts and
clinic reports were coded by the CCR [46,47]. These
were stage of disease at diagnosis (node negative, node
positive or distally metastasized), receipt of initial
surgery, type of surgery (lumpectomy or mastectomy),
receipt of adjuvant radiation therapy, chemotherapy or
hormone therapy, wait times from diagnosis to initial
surgery and from surgery to adjuvant therapies, receipt
of breast reconstruction surgery (post-mastectomy) and
survival time from diagnosis to death or last follow-up
at 10 years. All of these variables had less than 5% missing data. Tumor size (88.2%), histological grade (85.1%)
and hormone receptor statuses (estrogen and progesterone receptors, 93.3%) were also coded for the vast
majority of the sample. Various long wait criteria that
may be associated with recurrences, metastases or
shorter survival were explored [3,48-52].

Uninsured

Living in poverty
0.00–4.99

Breast cancer care

High Poverty

Prevalence (%) of households
Neighborhood
poverty

neighborhood poverty and primary payer are crosstabulated in Table 2. Women with breast cancer living in
high poverty California neighborhoods were one and a
half times as likely to be uninsured, more than twelve
times as likely to be primarily insured by Medicaid, but
only two-thirds as likely to be covered by a private insurer
as were their counterparts in low poverty neighborhoods.

Notes. PR = prevalence ratio, CI = confidence interval. A prevalence ratio of
1.00 was the between-place baseline. Middle and high poverty neighborhoods
were compared to low poverty neighborhoods on payer prevalence estimates.
Bolded PRs were statistically significant at p < .05.
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Descriptive profiles of the breast cancer patients in
our sample are displayed in Table 3. As planned, diverse
geographic places, large urban to rural, and types of
neighborhoods, high poverty to relatively affluent, were
represented. Demographically, our age-diverse sample of
younger working-age women (57.6%) and older women
of retirement age (42.3%) seems consistent with expectations. More than half of them were primarily covered by
a commercial, private insurer (53.6%). Given our oversampling of very poor neighborhoods, the relatively low
representation of the uninsured (10.9%) may seem surprising. Note though that most initial breast cancer care
takes place in hospitals where social workers work to
connect uninsured patients to any additional resources,
typically Medicaid or Medicare, for which they are qualified by virtue of being poor, older or disabled.
Statistical analyses

We used logistic regression models to test hypotheses
about the mediating and moderating effects of poverty
and payers in predicting binary (survived or not) allcause breast cancer survival [53-55]. Odds ratios (ORs)
and 95% confidence intervals (CIs) were estimated. Survival outcomes that were best predicted by main poverty
and payer effects and their interactions were analyzed
and reported: 8-year for node negative, 5-year for node
positive and 3-year for distally metastasized disease
(Hosmer-Lemeshow test [55,56]). ORs estimate the relative predictive weights of main and interacting effects.
However, under the circumstances of this study, where
both social exposures and key outcomes are common,
ORs probably overestimate rate ratios (RRs) [57]. So we
provided accompanying practical assessments more germane perhaps to clinical and policy significance. Rates
were directly adjusted for age and other relevant covariates that significantly and substantially confounded
poverty- or payer-breast cancer care relationships, using
this study’s sample as the standard and reported as rates
per 100 cases or percentages. Then we used standardized
RRs for between-group comparisons, with 95% CIs
derived from the Mantel-Haenszel χ2 test [58,59]. Statistical model tests (ORs with 95% CIs) are presented in
Tables 4 ,5, 6, 7 and 8 with accompanying “real world”
practical significance indices (RRs with 95% CIs) reported
as interpretive adjuncts in the text. Because some of our
subsample-based hypotheses could be deemed exploratory
we also reported as approaching significance any finding
that met the more liberal statistical criterion of p < .10.

Results
Interacting effects of poverty and health insurance on
breast cancer survival

Regression models for node negative, node positive and
metastasized breast cancer survival are displayed in
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Table 4. Substantial support for both mediation and
moderation hypotheses was observed for node negative
disease. The top left column shows significant main
effects of poverty (OR = 0.54) and payer (OR = 1.57)
when these factors entered regression models alone.
Moving down to the full model, consistent with mediation, in the presence of payer the effect of poverty
disappeared and the effect of adequate payers was
strengthened (OR = 1.89). The 8-year survival rate
among those insured privately or by Medicare (75.5%)
was nine percent greater than that of the uninsured or
those covered by Medicaid (69.0%, RR = 1.09, 95% CI
1.03, 1.15).
The hypothesis that the health insurance-survival relationship would be moderated by poverty was also supported for women with node negative disease. The
statistical interaction’s practical effect moderation is
depicted in the bottom of Table 4. Having adequate
health insurance seemed much more effective in low
poverty (OR = 1.81, 95% CI 1.11, 2.95) than in high poverty neighborhoods, where Medicare or private insurance did not seem any more effective than having
Medicaid or being uninsured (OR = 1.16, 95% CI 0.82,
1.62). Consistent with social capital theory, the 8-year
survival rate among women with node negative breast
cancer who lived in low poverty neighborhoods and
were primarily covered by Medicare or private insurers
(79.9%) was 13% greater than the survival rate among,
otherwise similar, women primarily covered by Medicaid
or who were uninsured (70.8%, RR = 1.13, 95% CI 1.02,
1.25). A somewhat smaller payer gradient was observed
in middle poverty neighborhoods (75.5% vs 68.4%, RR =
1.10, 95% CI 1.01, 1.20) and no such gradient was
observed in high poverty neighborhoods.
As for women with node positive and metastasized
breast cancer, only significant main effects were
observed. The practical 5-year survival effect of having
Medicare or private coverage, versus Medicaid or none,
for women with node positive disease was similar to that
observed for women with node negative disease. Their
respective survival rates were 73.6% and 66.2% (RR =
1.11, 95% CI 1.03, 1.19). And having such coverage
seems to have made a very large difference in the lives of
women diagnosed with metastasized disease. Those who
were adequately covered were much more likely to have
survived for 3 years (31.8%) than were the inadequately
covered (18.2%, RR = 1.75, 95% CI 1.11, 2.75).
Interacting effects of poverty and health insurance on
breast cancer diagnoses and treatments
Stage at diagnosis

Mediation and moderation hypothesis support was also
found for early diagnosis of node negative disease. In the
full regression model, the apparent effect of living in
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Table 3 Stratification, age, payer, staging, tumor and care characteristics of breast cancer patients diagnosed between
1996 and 2000 and followed until 2011
Sample

%

Sample

%

Stratification characteristics
Places

Poverty prevalence (%) in neighborhoods

Large urban

2,100

33.3

<5

2,100

33.3

Smaller urban

2,100

33.3

5–29

2,100

33.3

Rural

2,100

33.3

≥ 30

2,100

33.3

Age and primary payer characteristics
Age at diagnosis, y

Primary payers

25–44

904

14.3

Private insurers

3,376

53.6

45–54

1,386

22.0

Medicare

1,777

28.2

55–64

1,344

21.3

Medicaid

465

7.4

65–74

1,375

21.8

Uninsured

685

10.9

≥ 75

1,291

20.5
Staging characteristics at diagnosis

Summary stage

Size of tumor, mm

Local-regional

< 10

Node negative

4,035

66.2

Node positive

975

17.5

10–19

2,035

36.6

1,774

29.1

20–49

2,035

36.6

Distally metastasized

287

4.7

≥ 50

512

9.2

Missing data

204

3.2

Missing data

743

11.8

Tumor characteristics
Histological grade

Hormone receptor statuses

I, well differentiated

1,134

21.1

Estrogen positive

3,720

63.3

II, moderately

2,211

41.2

Progesterone positive

3,189

54.3

III/IV, poorly

2,019

37.6

Either positive

3,852

65.5

936

14.9

Missing data

422

6.7

Missing data

Cancer care characteristics
Surgery received

Wait time from diagnosis to surgery, d

Lumpectomy

3,025

48.4

≤7

2,699

45.8

Mastectomy

2,876

46.0

8–30

2,011

34.1

348

5.6

≥ 31

1,187

20.1

51

0.8

Missing data

4

0.1

2,843

45.4

44

0.7

≤ 60a

1190

42.9

61–90

451

16.3

91–180

687

24.8

≥ 181

446

16.1

69

2.4

≤ 30b

891

40.7

31–60

839

38.3

61–90

273

12.4

No surgery
Missing data
Received RT
Missing data

Wait time after surgery for RT, d

Missing data
Received chemotherapy
Missing data

2,299

37.6

185

2.9

Wait time after surgery for chemotherapy, d

≥ 91

188

8.6

Missing data

108

4.7
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Table 3 Stratification, age, payer, staging, tumor and care characteristics of breast cancer patients diagnosed between
1996 and 2000 and followed until 2011 (Continued)
Received HT

2,115

34.7

205

3.3

Missing data

Wait time after surgery for HT, d
≤ 30c

701

34.7

31–90

667

33.0

91–180

408

20.2

≥ 181

247

12.2

92

4.3

Missing data
Note. RT = radiation therapy, HT = hormone therapy.
a
A few (41) of these patients received RT prior to or without surgery.
b
One third (32.4%) of these patients received chemotherapy prior to or without surgery.
c
One fifth (18.5%) of these patients received HT prior to or without surgery.

Table 4 Logistic regression main effects and interactions of neighborhood poverty and primary payer by breast cancer
stage at diagnosis on survival
Local-Regional
Node negative disease

Distally Metastasized
Node positive disease

8 year survival
Predictor Variables

Sample

OR

5 year survival
(95% CI)

Sample

OR

3 year survival
(95% CI)

Sample

OR

(95% CI)

55

1.00

Single predictor models
Neighborhood poverty
< 5% poor

1,435

1.00

561

1.00

5-29% poor

1,353

0.73

(0.61, 0.88)

574

0.70

(0.53, 0.93)

97

0.76

(0.37, 1.59)

≥ 30% poor

1,247

0.54

(0.45, 0.65)

639

0.41

(0.31, 0.53)

135

0.63

(0.31, 1.29)

572

1.00

382

1.00

84

1.00

3,463

1.57

(1.44, 2.41)

203

2.51

Primary payer
Uninsured or Medicaid
Medicare or private

(1.27, 1.96)

1,392

1.86

(1.28, 4.92)

Full models
Neighborhood poverty
< 5% poor

1,435

1.00

561

1.00

55

1.00

5-29% poor

1,353

0.92

(0.67, 1.26)

574

0.72

(0.55, 0.96)

97

0.79

(0.38, 1.68)

≥ 30% poor

1,247

0.84

(0.50, 1.40)

639

0.44

(0.34, 0.58)

135

0.76

(0.36, 1.59)

382

1.00

84

1.00

(1.26, 2.84)

1,392

1.59

(1.22, 2.07)

203

2.40

(1.21, 4.79)

1,774

a

287

a

(0.39, 3.54)

Primary payer
Uninsured or Medicaid
Medicare or private
Poverty by payer

572

1.00

3,463

1.89

4,035

*

0.79

(0.60, 1.04)

1.20

(0.85, 1.69)

1.17

Poverty by payer interaction among women with node negative disease on 8 year survival
> 30% poor
Sample

OR

Uninsured or Medicaid

277

1.00

Medicare or private

970

1.16

5-29% poor
(95% CI)

Sample

OR

< 5% poor
(95% CI)

Sample

OR

(95% CI)

Primary payer

(0.82, 1.62)

186

1.00

1,167

1.57

(1.09, 2.27)

109

1.00

1,326

1.81

(1.11, 2.95)

Notes. OR = odds ratio, CI = confidence interval. All effects were age-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older. After age,
poverty and payer were accounted for, place (large urban, smaller urban or rural) and race/ethnicity (person of color [32.1%] or non-Hispanic white) did not enter
any of the full models. Bolded ORs were statistically significant at p < .05.
a
Null interaction was removed from the full model. * p < .10.
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Table 5 Logistic regression main effects and interactions of neighborhood poverty and primary payer on breast cancer
stage at diagnosis
Node negative disease
Predictor Variables

Sample

OR

Tumor < 20 mm
(95% CI)

Sample

OR

(95% CI)

Single predictor models
Neighborhood poverty
< 5% poor

1,833

1.00

5-29% poor

1,760

0.94

≥ 30% poor

1,723

0.75

888

1.00

4,428

1.42

1,704

1.00

(0.81, 1.08)

1,639

0.88*

(0.75, 1.02)

(0.65, 0.88)

1,575

0.61

(0.52, 0.71)

796

1.00

4,122

1.37

Primary payer
Uninsured or Medicaid
Medicare or private

(1.21, 1.65)

(1.16, 1.61)

Full models
Neighborhood poverty
< 5% poor

1,833

1.00

1,704

1.00

5-29% poor

1,760

1.27

(0.88, 1.84)

1,639

0.89

(0.76, 1.04)

≥ 30% poor

1,723

1.06

(0.74, 1.52)

1,575

0.63

(0.54, 0.73)

796

1.00

(1.23, 2.44)

4,122

1.23

(1.04, 1.45)

4,918

a

(0.93, 1.45)

Primary payer
Uninsured or Medicaid
Medicare or private
Poverty by payer

888

1.00

4,428

1.73

5,316

*

0.72

(0.49, 1.06)

1.16

Poverty by payer interaction on node negative disease at diagnosis
> 5% poor
Predictor Variables

Sample

OR

730

1.00

2,753

1.28

< 5% poor
(95% CI)

Sample

OR

158

1.00

1,675

1.76

(95% CI)

Primary payer
Uninsured or Medicaid
Medicare or private

(1.07, 1.53)

(1.25, 2.48)

Notes. OR = odds ratio, CI = confidence interval. All effects were age and grade-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older; and
well, moderately or poorly differentiated. Bolded ORs were statistically significant at p < .05.
a
Null interaction was removed from the full model. * p < .10.

high poverty neighborhoods disappeared, whereas the
effect of payer (OR = 1.73) seemed strengthened and a
poverty by payer interaction that approached statistical
significance was detected (left column of Table 5).
Evidence of this moderation of the effect of payer by
poverty is depicted in the bottom of the table: low poverty
(OR = 1.76) and middle to high poverty neighborhoods
(OR = 1.28). In low poverty neighborhoods, women with
Medicare or private health insurance were nearly 20%
more likely (69.1%) to have been diagnosed with node
negative disease than were the uninsured or those covered
by Medicaid (58.3%, RR = 1.19, 95% CI 1.05, 1.34).
Whereas the effectiveness of such health insurers was
much smaller in middle to high poverty neighborhoods,
where their respective early diagnosis rates were 65.3%
and 61.5% (RR = 1.06, 95% CI 1.00, 1.13). As for tumor
size at diagnosis, only significant main effects of high poverty (OR = 0.63) and payer (OR = 1.23) were observed,
and the practical size of the payer-tumor size relationship
was similar to that of the payer-early stage relationship.

Waits for care

Wait times for initial surgery and adjuvant radiation
therapy of local-regional breast cancers are displayed in
Table 6. Two findings are consistent with mediation and
moderation hypotheses. First, payer clearly mediated the
poverty-wait time relationship among women who
received radiation therapy without chemotherapy as the
apparent effect of poverty disappeared in the presence of
the highly significant effect of payer (OR = 0.55, middle
column of Table 6). In fact, the rate of waiting for more
than three months after surgery for radiation therapy
among those covered by Medicare or private insurers
(13.5%) was less than half that of the uninsured or
Medicaid covered (28.6%, RR = 0.47, 95% CI 0.36, 0.61).
Second, poverty seemed to moderate the payer-wait time
relationship among women who received adjuvant radiation therapy with chemotherapy as there was an effect of
payer that approached statistical significance in middle
and low poverty neighborhoods (OR = 0.70, p < .10), but
not in high poverty neighborhoods (bottom of Table 6).
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Table 6 Logistic regression main effects and interactions of neighborhood poverty and primary payer on wait times
from diagnosis to surgery and from surgery to radiation therapy among women with local-regional breast cancer
[No chemotherapy]

Predictor variables

[Had chemotherapy]

Waited > 60 days

Waited > 90 days

Waited > 210 days

diagnosis to surgery

surgery to radiation therapy

surgery to radiation therapy

Sample

OR

(95% CI)

Sample

OR

(95% CI)

Sample

OR

(95% CI)

Single predictor models
Neighborhood poverty
< 5% poor

1,975

1.00

640

1.00

403

1.00

5-29% poor

1,901

1.21

(0.92, 1.59)

507

1.06

(0.71, 1.57)

382

0.84

(0.59, 1.18)

≥ 30% poor

1,841

1.88

(1.46, 2.43)

382

1.50

(1.01, 2.25)

361

0.89

(0.63, 1.26)

224

1.00

252

1.00

(0.48, 0.77)

1,305

0.52

(0.35, 0.77)

894

0.87

403

1.00

Primary payer
Uninsured or Medicaid
Medicare or private

934

1.00

4,783

0.61

(0.62, 1.23)

Full models
Neighborhood poverty
< 5% poor

1,975

1.00
*

640

1.00

5-29% poor

1,901

1.95

(0.94, 4.03)

507

1.02

(0.69, 1.52)

382

1.92

(1.02, 3.61)

≥ 30% poor

1,841

2.86

(1.40, 5.82)

382

1.37

(0.91, 2.06)

362

1.54

(0.83, 2.84)

934

1.00

224

1.00

252

1.00

Primary payer
Uninsured or Medicaid
Medicare or private
Poverty by payer

4,783

1.13

(0.56, 2.29)

1,305

0.55

(0.37, 0.82)

894

0.65

(0.42, 1.00)

5,717

0.52*

(0.25, 1.11)

1,529

1.03a

(0.64, 1.67)

1,146

1.96*

(0.97, 3.97)

Poverty by payer interaction on surgical wait times of more than 2 months
> 5% poor
Sample

OR

< 5% poor
(95% CI)

Sample

OR

169

1.00

1,806

1.18

(95% CI)

Primary payer
Uninsured or Medicaid
Medicare or private

765

1.00

2,977

0.58

(0.44, 0.75)

(0.58, 2.39)

Poverty by payer interaction among women who received chemotherapy on post-surgical wait times of more than 7
months for RT
> 30% poor
Sample

OR

Uninsured or Medicaid

121

1.00

Medicare or private

240

0.96

< 30% poor
(95% CI)

Sample

OR

131

1.00

654

0.70*

(95% CI)

Primary payer

(0.59, 1.57)

(0.47, 1.03)

Notes. OR = odds ratio, CI = confidence interval. All effects were age and stage-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older; and
node positive or node negative breast cancer. Bolded ORs were statistically significant at p < .05.
a
Null interaction was removed from the full model. * p < 10.

The rate of waiting for more than seven months after surgery for radiation therapy among those covered by Medicare or private insurers (16.2%) was approximately 25%
lower than that of the uninsured or Medicaid covered
(21.8%, RR = 0.74, 95% CI 0.52, 1.06, p < .10).
Surgical wait times fit a different pattern. First, there was
a very large effect of poverty (OR = 2.86). Women who
lived in high poverty neighborhoods (12.7%) were two and
a half times as likely to have waited two months or more
for surgery than were women who lived in low poverty

neighborhoods (5.0%, RR = 2.54, 95% CI 2.05, 3.15). Second, in the context of such a large effect of poverty, it
seems that having adequate health insurance confers a protective effect in high and middle poverty (OR = 0.58), but
not in low poverty neighborhoods. In higher poverty
neighborhoods, adequately insured women were about a
third less likely than were uninsured or Medicaid
insured women to have waited two months or more.
Such respective long wait rates were 6.9% and 10.5%
(RR = 0.66, 95% CI 0.52, 0.96). Such long surgical wait
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Table 7 Logistic regression main effects and interactions of neighborhood poverty and primary payer on receipt of
initial and adjuvant therapies among women with node negative breast cancer
Radiation therapya
Predictor variables

Sample

OR

Hormone therapyb

Chemotherapy

(95% CI)

Sample

OR

(95% CI)

Sample

OR

(95% CI)

Single predictor models
Neighborhood poverty
< 5% poor

877

1.00
*

1,327

1.00

932

1.00

5-29% poor

762

0.80

(0.63, 1.01)

1,232

1.18

(0.94, 1.46)

756

0.77

(0.63, 0.93)

≥ 30% poor

611

0.63

(0.49, 0.81)

1,113

0.96

(0.76, 1.22)

611

0.70

(0.56, 0.86)

980

1.00

1,627

1.00

1,002

1.00

1,270

1.40

(0.81, 1.24)

1,297

1.38

Primary payer
All others
Private

(1.12, 1.75)

2,045

1.00

(1.14, 1.66)

Full models
Neighborhood poverty
< 5% poor

877

1.00

1,327

1.00

932

1.00

5-29% poor

762

0.62

(0.44, 0.87)

1,232

1.16

(0.93, 1.44)

756

0.78

(0.64, 0.95)

≥ 30% poor

611

0.51

(0.37, 0.72)

1,113

0.77

(0.54, 1.10)

611

0.73

(0.59, 0.90)

1,627

1.00

1,002

1.00

(0.68, 1.40)

2,045

0.87

(0.66, 1.13)

1,297

1.32

(1.09, 1.60)

2,299

c

(0.79, 1.21)

Primary payer
All others
Private
Poverty by payer

980

1.00

1,270

0.97

2,250

1.61

(1.05, 2.46)

*

3,672

1.43

(0.93, 2.19)

0.98

Poverty by payer interaction on receipt of adjuvant radiation therapy
> 5% poor
Sample

OR

All others

651

1.00

Private

722

1.56

< 5% poor
(95% CI)

Sample

OR

329

1.00

548

1.06

(95% CI)

Primary payer

(1.19, 2.03)

(0.70, 1.61)

Poverty by payer interaction on receipt of chemotherapy
> 30% poor
Sample

OR

639

1.00

< 30% poor
(95% CI)

Sample

OR

988

1.00

1,571

0.86

(95% CI)

Primary payer
All others
Private

474

*

1.39

(0.94, 2.06)

(0.65, 1.13)

Notes. OR = odds ratio, CI = confidence interval. All effects were age and tumor size-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older;
and less than 10, 10–19 and 20–50 mm or larger. Bolded ORs were statistically significant at p < .05.
a
Among women who received breast conserving surgery. b Among women with hormone receptor positive tumors.
c
Null interaction was removed from the full model. * p < .10.

rates were identical (5.5%) for both payer groups in low
poverty neighborhoods.
Receipt of adjuvant therapies

The effects of poverty and payer on the receipt of adjuvant therapies for node negative and node positive breast
cancers are, respectively, displayed in Tables 7 and 8. It
should be noted that nearly all of them received initial
surgery (98.5%) and such receipt was not associated with
poverty or any payers. For women with node negative
disease having private health insurance seemed to make
the biggest difference and for women with node positive
disease having any form of health insurance seemed to

confer substantial access advantages over the uninsured.
For women with node negative disease, in addition to
having large main disadvantageous effects on access to radiation and hormone therapies, poverty seemed to moderate the effect that private insurance had in providing
access to both adjuvant radiation and chemotherapies.
Their poverty by payer interactions were, respectively,
significant or nearly significant. The interactions depicted
in the bottom of the table indicated protective effects
conferred by having private health insurance specific to
higher poverty neighborhoods. In high to middle poverty neighborhoods more than three-quarters of the
women who had received breast conserving surgery and
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Table 8 Logistic regression main effects and interactions of neighborhood poverty and primary payer on receipt of
initial and adjuvant therapies among women with non-distally metastasized, node positive breast cancer
Chemotherapya

Radiation therapy
Predictor variables

Sample

OR

(95% CI)

Sample

OR

Hormone therapyb
(95% CI)

Sample

OR

364

1.00

(95% CI)

Single predictor models
Neighborhood poverty
< 5% poor

497

1.00

5-29% poor

525

0.82

≥ 30% poor

568

0.75

174

1.00

1,416

0.94

364

1.00

(0.64, 1.05)

321

1.01

(0.73, 1.40)

333

1.19

(0.88, 1.62)

(0.59, 0.96)

393

0.78

(0.56, 1.07)

335

0.90

(0.66, 1.23)

107

1.00

103

1.00

929

0.98

Primary payer
Uninsured
Any insurance

(0.76, 1.16)

931

1.12

(0.72, 1.75)

(0.64, 1.50)

Full models
Neighborhood poverty
< 5% poor

497

1.00

324

1.00

364

1.00

5-29% poor

525

0.82

(0.63, 1.05)

321

1.07

(0.77, 1.49)

333

1.32*

(0.96, 1.82)

≥ 30% poor

568

0.73

(0.57, 0.93)

393

0.86

(0.62, 1.21)

335

0.90

(0.66, 1.22)

174

1.00

107

1.00

1,416

0.87

931

0.64

Primary payer
Uninsured
Any insurance
Poverty by payer

1,590

c

0.73

(0.70, 1.09)
(0.48, 1.12)

*

1,038

0.59

103

1.00

(0.32, 1.29)

929

0.68

(0.41, 1.15)

(0.34, 1.01)

1,032

0.33

(0.13, 0.82)

Poverty by payer interaction on receipt of chemotherapy
> 5% poor
Sample

OR

75

1.00

< 5% poor
(95% CI)

Sample

OR

(95% CI)

Primary payer
Uninsured
Any insurance

639

*

1.63

(0.91, 2.90)

32

1.00

292

0.55

(0.25, 1.17)

Poverty by payer interaction on receipt of hormone therapy
> 30% poor
Sample

OR

36

1.00

299

0.72

5-29% poor
(95% CI)

Sample

OR

< 5% poor
(95% CI)

Sample

OR

35

1.00

329

0.59

(95% CI)

Primary payer
Uninsured
Any insurance

(0.34, 1.52)

32

1.00

301

2.16

(1.00, 4.69)

(0.28, 1.26)

Notes. OR = odds ratio, CI = confidence interval. Effects on radiation and hormone therapies were age and tumor size-adjusted and effects on chemotherapy were
adjusted for age and the receipt of radiation therapy across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older; less than 10, 10–19 and 20–50 mm or
larger; and received radiation therapy or not. Bolded ORs were statistically significant at p < .05.
a
Among women who received mastectomies. b Among women with hormone receptor positive tumors.
c
Null interaction was removed from the full model. * p < .10.

were privately insured received adjuvant radiation therapy (77.3%), whereas, only about two-thirds of otherwise similar women who were covered by Medicare,
Medicaid or were uninsured did (67.6%, RR = 1.15,
95% 1.07, 1.23). No such effect was observed in low
poverty neighborhoods. In high poverty neighborhoods
there was an even larger effect of being privately
insured on chemotherapy receipt. Respectively, 24.6%
and 19.6% of privately insured and other insured or uninsured women received chemotherapy (RR = 1.26, 95%
1.00, 1.58). There was no significant effect of being privately insured in lower poverty neighborhoods. As for

hormone therapy, only significant main effects of poverty and private insurance were observed. Again, having
private insurance or not made a big difference in access
to hormone therapy (50.7% versus 41.7%, RR = 1.22,
95% CI 1.12, 1.33).
For women with node positive disease having any
form of health insurance seemed to confer substantial
advantages over the uninsured. Poverty again moderated the effects of these payers on access to chemotherapy and hormone therapy (middle and right
columns of Table 8). Large care gaps were observed
among the uninsured, particularly among the
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uninsured that lived in the poorest neighborhoods.
Such residents of high poverty neighborhoods who
had any health insurance were much more likely to
have received chemotherapy (85.5% vs 65.4%, RR =
1.31, 95% CI 1.16, 1.48). And such insured residents
of middle poverty neighborhoods seemed more likely
to have received hormone therapy (53.3% versus
36.6%, RR = 1.46, 95% CI 0.94, 2.27, p < .10). Not
surprisingly, as it is not typically the first adjuvant
treatment choice for node positive breast cancer, no
significant payer effect was observed for radiation
therapy.
Specialized care among women with non-metastasized
disease

Next, we examined surgical procedures that came into
practice (sentinel lymph node biopsy [SLNB]) or continued to proliferate during the study period (breast conserving surgery [BCS]) or that are not yet prevalently
provided (breast reconstruction surgery [BRS]. There
were similar patterns of Medicaid main effects and poverty by private insurance interactions for BCS and BRS.
Those with Medicaid were less likely to receive BCS
(37.1% vs 50.4%, RR = 0.74, 95% CI 0.65, 0.85) and much
less likely to receive BRS (3.2% vs 13.7%, RR = 0.23, 95%
CI 0.12, 0.46) than other women. And private insurance
facilitated access to both BCS (50.2% vs 41.6%, RR = 1.21,
95% CI 1.07, 1.36) and BRS (12.9% vs 5.9%, RR = 2.19,
95% CI 1.55, 3.09) in high and middle poverty neighborhoods, but not in low poverty ones. Medicare or private
health insurance completely mediated the disadvantaging
effect of poverty on receipt of SLNB. Moreover, such coverage seemed to greatly facilitate access in low poverty neighborhoods (14.8% vs 6.6%, RR = 2.24, 95% CI 1.19, 4.20)
more modestly facilitate access in middle poverty neighborhoods (10.8% vs 6.2%, RR = 1.74, 95% CI 1.04, 2.91), but
seemed to have no effect in high poverty neighborhoods
were very few women (6.3%) received such an innovative
procedure.
Explorations of palliative care among women with
metastasized disease

There seemed to be main effects of health insurance,
but not poverty on the receipt of surgery and chemotherapy. Those with any insurance were about 50% more
likely than the uninsured to have received surgery
(46.7% vs 31.7%, RR = 1.47, 95% CI 0.94, 2.29, p < .10)
and those with Medicare or private coverage were 25%
more likely to have received chemotherapy than the uninsured or Medicaid covered (58.8% vs 47.2%, RR = 1.25,
95% CI 0.98, 1.60, p < .10). A protective effect of private
insurance on the receipt of radiation therapy was only
observed in middle poverty neighborhoods. More than
half of such privately insured women received radiation
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therapy (52.6%), whereas only about a third of those
covered by other than commercial insurers or who were
uninsured did (35.3%, RR = 1.49, 95% CI 0.95, 2.35,
p < .10). No significant main or interacting effects of
health insurance were observed on hormone therapy.
There was, however, quite a strong effect of poverty.
Women in high poverty neighborhoods were only about
half as likely to receive hormone therapy as were their
counterparts in low poverty neighborhoods (36.4% vs
69.2%, RR = 0.53, 95% CI 0.33, 0.84).

Discussion
We found strong support for our hypothesis that health
insurance mediates the poverty-breast cancer survival
relationship. Evidence of survival mediation was
observed for women with the most common and treatable type of breast cancer, node negative. The effect of
poverty disappeared in the presence of Medicare or
private insurance. Women who were so insured were
advantaged on survival compared to the uninsured or
those insured by Medicaid. Evidence of insurance effect
moderation by poverty was also observed for women
with node negative disease. The survival advantaging
effect of Medicare or private insurance was strongest in
low poverty neighborhoods, less strong in moderately
poor neighborhoods and nonexistent in high poverty
neighborhoods. This same pattern of mediated and
moderated effects was also observed for stage at diagnosis, waits for adjuvant radiation therapy and for receipt
of sentinel lymph node biopsies. These findings are consistent with the theory that more facilitative social and
economic capital is available in more affluent neighborhoods where women with breast cancer may be better
able to absorb the indirect and direct, but uncovered,
costs of care.
We did not find support for our hypothesis that
Medicaid would also mediate the effect of poverty as we
had for women with colon cancer [27]. However, this
study’s sample of women with breast cancer and the previous study’s sample of women with colon cancer were
demographically distinct. The women with breast cancer
were much younger. They were twice as likely to be of
pre-retirement age and 35% more likely to be covered by
a commercial insurer. Younger women with breast
cancer, more than half of whom had private health insurance, benefited greatly from having it. Whereas, older
women with colon cancer, two-thirds of whom did not
have private insurance, seemed to benefit relatively more
from Medicaid coverage.
Medicare or private insurers were the primary payers
for the care of eight out of every ten women in this
study. It seems that the effectiveness of these, most
prevalent, health insurance programs, public and private,
are significantly impacted by the availability of other
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resources. In more well to do neighborhoods where social and economic capital abounds most women with
breast cancer seem able to absorb the uncovered costs
of cancer care. But high poverty neighborhoods, with
their relative lack of such capital reserves, seem to
remain places of “true disadvantage” [6], especially for
the women who live there. Not only are they much more
likely to be uninsured or underinsured, but even when
insured such insurance programs seem to be less effective for them there than they are in less impoverished
neighborhoods.
As for treatments, main and moderator effects indicative of protection, particularly in high poverty neighborhoods were observed for women with private health
insurance. All of the following benefits of having commercial coverage among women living in high poverty
neighborhoods were observed: shorter surgical waits,
better access to BCS as well as to adjuvant radiation,
chemo- and hormone therapies. And for women who
received mastectomies, those with private insurance
were more than twice as likely to have also received
BRS.
These findings may seem counter hypothetical, but an
extension of our health insurance-social capital theory
could explain them. In such high poverty neighborhoods, having private health insurance could itself be
deemed an important form of social capital. Especially in
such vulnerable places, private health insurance seems
to operate to the advantage of its holders. One way that
it may operate is through its probable association with
higher quality primary care. Privately insured women are
more likely to have more established, continuous relationships with primary care physicians. Such relationships are known to provide myriad benefits: preventive
surveillance, referral to and follow-up of specialist care,
and advocacy and coordination throughout care processes [60,61]. Clearly, such could make a very big difference in the life of a woman with breast cancer, especially
if she otherwise has limited personal and community
resources available to her. This is not to say that high
poverty neighborhoods are devoid of such resources. For
example, evidence has been accumulating about the possible health benefits of living in certain relatively homogeneous communities such as Mexican American
barrios [62,63]. Though such ethnic concentrations tend
to be associated with concentrations of poverty, it seems
that people and institutions in these communities provide quite a bit of effective social and economic support
to one another. Despite their resiliencies though, gaps in
access to key resources including primary care have been
identified there. So it stands to reason that private insurance and attendant primary care could operate to potentiate the strengths and resiliencies that already exist
in such high poverty neighborhoods.
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Payer effect sizes

This study’s payer effect sizes estimated with standardized rate ratios ranged from 1.06 to 2.25. Those most
hypothetically central, the effects of having Medicare or
private insurance on early diagnosis and survival among
women with node negative breast cancer in high poverty
neighborhoods, ranged from 1.10 to 1.19. Though significant in a statistical sense, they might be thought
small for clinical practice or policy guidance. We think
such would be an interpretive error for the following
reasons. The attribution of risk at the population level is
a function of three factors of which effect size is only
one. It is also important to consider the size of the
population at risk as well as the prevalence of exposures
to the risk factors being studied. In this instance, the
central exposure or risk factor to be mediated is a social
one, that is, residence in a high poverty neighborhood.
The other social exposure of interest or risk factor is the
risk of being inadequately insured, that is, of being
insured by Medicaid or uninsured. More than forty percent of the non-elderly, non-disabled California population or more than 13 million people are so affected. The
national estimate approaches 100 million [64-66]. At the
time of this study approximately 34 million Americans
were poor and nearly 10 million of them lived in high
poverty neighborhoods [35,67]. Regrettably, being uninsured, Medicaid insured or poor are not rare “exposures”
in California or America. And nearly a quarter of a million American women are newly diagnosed with breast
cancer each year [68]. So a change in relative risk of ten
to twenty percent could affect more than 10 thousand
women with breast cancer in California and nearly 50
thousand women in the United States each year. In
terms of population attributable risk, we would deem
these extraordinarily large effects.
Potential limitations

Our use of ecological poverty measures might suggest
alternative explanations for our results. One may wonder
if the racial/ethnic composition of high poverty neighborhoods, rather than their concentration of the poor,
accounted for the care and survival differences we
observed. We do not think so for the following reasons.
First, numerous recent US studies of breast cancer care
and survival have found that socioeconomic differences
explain most racial-group differences [69-74]. Second,
after we accounted for age, and stage as well as the main
and interacting effects of poverty and health insurance
in these analyses, race/ethnicity was not significantly
associated with survival. And third, our research group
observed that health insurance disparities can explain essentially all of the breast cancer care disparities observed
among our sample’s largest ethnic minority group
(15.7%), Mexican Americans [75,76]. In short, while not
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refuting the importance of race, ethnicity and culture in
cancer care [77-79], our analyses suggest that having
adequate health insurance is probably much more
important.
There has been a large unmet need for research on
the validity of ecological measures of SES often used
in public health research. Wilson and Jargowsky and
others have added much knowledge on high poverty
neighborhood measures [6-8,35,36] and our research
group has done work to advance understandings of
poor neighborhoods, analogous to this study’s middle
poverty neighborhoods [80,81]. They seem prevalently
represented by not only the poor, but the near poor
and working poor as well as lower-middle and middle
class people. This study added further to our knowledge about vulnerable neighborhoods. For example,
steep gradients were observed for various types of
health insurance across low (e.g., baseline Medicaid
coverage) to high poverty neighborhoods (prevalence
more than 12-fold greater [82,83]). This new knowledge about the validity of ecological poverty measures may advance our understandings about the
contexts in which very poor Americans live. Therefore, our findings are probably not prone to ecological
fallacy. They may, in fact, help researchers to better
understand contextual measures of SES and so avoid
individualistic fallacies of inference [84,85].
Another possible limitation of our study was incomplete information on outpatient treatments [51,86].
Such data are more difficult for cancer registries to
collect than inpatient data. However, the California
breast cancer registry has been enhanced well beyond
the norm and has been shown to be nearly complete
for chemotherapy data [34,87]. In addition, analyses
of disease stage, hospital-based surgery and survival
were unlikely to have been affected [88], and missing
radiation therapy and chemotherapy data were not
prevalent in our sample. Finally, we focused on overall survival, rather than cancer-specific survival. Although vital status and length of overall survival are
highly accurate in cancer registries, the underlying
cause of death probably is not [89-91]. Although
death certificate error was a likely limitation, we did
systematically replicate our central all-cause survival
hypothesis tests with cancer-specific ones. If anything,
our overall survival effects were slight underestimates
of cancer-specific ones [90]. And the underlying cause
of many deaths not coded as cancer mortality can be
directly associated with lack of treatment or with cancer treatment complications [92]. For all of these
reasons, we think overall survival a valid and policytelling outcome. And such would clearly have had no
impact on other indices of breast cancer care such as
diagnoses and treatments.
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Conclusions
America’s multi-tiered health insurance system mediates
the quality of breast cancer care. The system is inequitable
and unjust as it advantages the well insured and the well
to do. Recent health care reforms ought to be enacted
across all 50 states in ways that are consistent with their
federal legislative intent, that high quality health care be
truly available to all.
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